Search Results - "van den Reek, J"

Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide by van Muijen, M. E., van der Schoot, L. S., van den Reek, J. M. P. A., de Jong, E. M. G. J.

“…Dose reduction (DR) of biologics, where possible, seems promising for more efficient use of expensive biologics. For implementation of DR strategies, it is…”
Get full text

Patients’ perspectives towards biologic dose reduction in psoriasis: a qualitative study by van der Schoot, L. S., Verhoef, L. M., van Ee, I., van Oort, F. P. A. H., Pieterse, A. H., Seyger, M. M. B., de Jong, E. M. G. J., van den Reek, J. M. P. A.

“…Dose reduction of biologics for psoriasis could contribute to more efficient use of these expensive medicines. Evidence on opinions of patients with psoriasis…”
Get full text

The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting by Menting, S.P., van den Reek, J.M.P.A., Baerveldt, E.M., de Jong, E.M.G.J., Prens, E.P., Lecluse, L.L.A., Wolbink, G.J., Van der Kleij, D., Spuls, Ph.I., Rispens, T.

Get full text

Drug survival for azathioprine and enteric-coated mycophenolate sodium in a long-term daily practice cohort of adult patients with atopic dermatitis by van der Schaft, J., Politiek, K., van den Reek, J.M.P.A., Kievit, W., de Jong, E.M.G.J., Bruijnzeel-Koomen, C.A.F.M., Schuttelaar, M.L.A., de Bruin-Weller, M.S.

Get full text

Data‐driven prediction of biologic treatment responses in psoriasis: steps towards precision medicine by Schoot, L. S., Reek, J. M. P. A.

“…Linked Article: Geifman et al. Br J Dermatol 2021; 185:825–835…”
Get full text

Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis by van den Reek, J.M.P.A., van Lümig, P.P.M., Driessen, R.J.B., van de Kerkhof, P.C.M., Seyger, M.M.B., Kievit, W., de Jong, E.M.G.J.

“…Summary Background Long‐term data of etanercept drug survival in patients with psoriasis in daily practice are scarce. Objectives The primary objective was to…”
Get full text

Determinants of omalizumab drug survival in a long‐term daily practice cohort of patients with chronic urticaria by Spekhorst, L. S., van den Reek, J. M. P. A., Knulst, A. C., Röckmann, H.

Get full text

Dose reduction of biologics in patients with plaque psoriasis: a review by van Riel, C A M, Michielsens, C A J, van Muijen, M E, van der Schoot, L S, van den Reek, J M P A, de Jong, E M G J

“…Dose reduction (DR) of first-generation biologics for plaque psoriasis (TNF-alpha inhibitors (i) and interleukin (IL)-12/23i) has been described in a previous…”
Get full text

Drug survival of methotrexate treatment in hand eczema patients: results from a retrospective daily practice study by Politiek, K., van der Schaft, J., Christoffers, W.A., Coenraads, P.J., van den Reek, J.M.P.A., de Jong, E.M.G.J., de Bruin-Weller, M.S., Schuttelaar, M.L.A.

Get full text

Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab by van Muijen, Marloes E., Atalay, S., van Vugt, L. J., Vandermaesen, L. M. D., van den Reek, J. M. P. A., de Jong, E. M. G. J.

“…Background Personal treatment goals have been systematically investigated in psoriasis patients with active but not in controlled disease. Objectives To…”
Get full text

Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review by Michielsens, C. A. J., van Muijen, M. E., Verhoef, L. M., van den Reek, J. M. P. A., de Jong, E. M. G. J

“…Introduction Biologics serve as a cornerstone in psoriasis treatment, with low disease activity or sometimes even clinical remission as a realistic treatment…”
Get full text

A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis by van Vugt, L.J., van den Reek, J.M.P.A., Coenen, M.J.H., de Jong, E.M.G.J.

“…Summary Background Biologics are indicated for treating moderate‐to‐severe psoriasis. As the number of biologics registered for the treatment of psoriasis…”
Get full text

The lifestyle of psoriasis patients and their motivation to change by Al‐Gawahiri, M., Reek, J. M. P. A., Acht, M. R., Evers, A. W. M., Jong, E. M. G. J., Seyger, M. M. B.

Get full text

Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry by Zweegers, J., van den Reek, J.M.P.A., van de Kerkhof, P.C.M., Otero, M.E., Kuijpers, A.L.A., Koetsier, M.I.A., Arnold, W.P., Berends, M.A.M., Weppner-Parren, L., Ossenkoppele, P.M., Njoo, M.D., Mommers, J.M., van Lümig, P.P.M., Driessen, R.J.B., Kievit, W., de Jong, E.M.G.J.

“…Summary Background Predictors for successful treatment are important for personalized medicine. Predictors for drug survival of biologics in psoriasis have…”
Get full text

Predicting treatment success with biologics in psoriasis by Reek, J.M.P.A.

“…Linked Article: Mourad et al. Br J Dermatol 2019; 181:450–458…”
Get full text

Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis by van der Schaft, J., Politiek, K., van den Reek, J.M.P.A., Christoffers, W.A., Kievit, W., de Jong, E.M.G.J., Bruijnzeel-Koomen, C.A.F.M., Schuttelaar, M.L.A., de Bruin-Weller, M.S.

“…Summary Background Long‐term data of ciclosporin A (CsA) treatment in daily practice in patients with severe atopic dermatitis (AD) are lacking. Objectives To…”
Get full text

Female patients are less satisfied with biological treatment for psoriasis and experience more side‐effects than male patients: results from the prospective BioCAPTURE registry by van der Schoot, L.S., van den Reek, J.M.P.A., Groenewoud, J.M.M., Otero, M.E., Njoo, M.D., Ossenkoppele, P.M., Mommers, J.M., Koetsier, M.I.A., Berends, M.A.M., Arnold, W.P., Peters, B., Andriessen, M.P.M., Den Hengst, C.W., Kuijpers, A.L.A., de Jong, E.M.G.J.

“…Background Female sex has been reported as a predictor for treatment discontinuation with biological therapies for psoriasis, although reasons remain unclear…”
Get full text

Exclusion by age, cardiovascular comorbidity and malignancies are the main factors that impact generalizability of evidence from trials to the real‐world situation in older adults with psoriasis by Haar, E. L. M., Reek, J. M. P. A., Bruin, E. E., Bronkhorst, E. M., Borgonjen, R. J., Kleinpenning, M. M., Kop, E. N., Visch, M. B., Kerkhof, P. C. M., Jong, E. M. G. J., Lubeek, S. F. K.

Get full text

Children with psoriasis and COVID‐19: factors associated with an unfavourable COVID‐19 course, and the impact of infection on disease progression (Chi‐PsoCov registry) by Zitouni, J., Bursztejn, A.‐C., Belloni Fortina, A., Beauchet, A., Di Lernia, V., Lesiak, A., Thomas, J., Topkarci, Z., Murashkin, N., Brzezinski, P., Torres, T., Chiriac, A., Luca, C., McPherson, T., Akinde, M., Maruani, A., Epishev, R., Vidaurri de la Cruz, H., Luna, P.C., Amy de la Bretêque, M., Lasek, A., Bourrat, E., Bachelerie, M., Mallet, S., Steff, M., Bellissen, A., Neri, I., Zafiriou, E., Reek, J.M.P.A., Sonkoly, E., Mahil, S.K., Smith, C.H., Flohr, C., Bachelez, H., Mahé, E.

“…Background The COVID‐19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data…”
Get full text

National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure by van der Schoot, L. S., Baerveldt, E. M., van Enst, W. A., Menting, S. P., Seyger, M. M. B., Wanders, S. L., van Ee, I., Pieterse, A. H., van den Reek, J. M. P. A., de Jong, E. M. G. J.

“…Dose reduction of biologics for psoriasis is applied in daily practice, although guidelines are lacking. Striving for clear criteria is important, as it leads…”
Get full text